Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of cholesterol-lowering therapy.

Vascular pharmacology - 1 Feb 2006

Schmitz Gerd, Langmann Thomas

Abstract excerpt

The prevention of cardiovascular disease is critically dependent on lipid-lowering therapy, including 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), cholesterol absorption inhibitors, bile acid resins, fibrates, and nicotinic acid. Although these drugs are generally well tolerated, severe adverse effects can occur in a minority of patients. Furthermore, a subset of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Cholesterol Ester Transfer Proteins
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycoproteins

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hydroxymethylglutaryl CoA Reductases

Share to Hypercholesterolemia

Share to Muscular Diseases

Source

Identifiers

PMID: 16337220
DOI: 10.1016/j.vph.2005.07.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of cholesterol-lowering therapy.PMID 16337220Read ↗

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart DiseaseSemantic proximity Read ↗

The pharmacogenomics of statins.Semantic proximity Read ↗

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for DyslipidemiaSemantic proximity Read ↗

Clinical implications of pharmacogenomics of statin treatmentSemantic proximity Read ↗

Genetics and personalized medicine--a role in statin therapy?Semantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

Clinical implications of pharmacogenetic variation on the effects of statins.Semantic proximity Read ↗

Pharmacogenomics, lipid disorders, and treatment options.Semantic proximity Read ↗

Pharmacogenetic study of statin therapy and cholesterol reduction.Semantic proximity Read ↗

Gene-drug interactions identify genomic loci that enhance statin effectiveness in lowering LDL cholesterolSemantic proximity Read ↗

Statins personalized.Semantic proximity Read ↗

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.